Polyrizon Announces Successful Results for NASARIX™ Biocompatibility Program, Supporting Advancement Towards First in Human Clinical Trial
Polyrizon Announces Successful Results for NASARIX™ Biocompatibility Program, Supporting Advancement Towards First in Human Clinical Trial
Polyrizon Makes Strong Progress: Receives Central IRB Approval for its Allergy Blocker Clinical Trial
Polyrizon Receives Notice of U.S. Patent Publication for Mucoadhesive Drug Delivery Platform
Polyrizon Advances NASARIX™ Development with Key Human Study to Characterize Nasal Residence Time and Support FDA Regulatory Pathway
Polyrizon Receives Notice of European Patent Publication for Innovative Mucoadhesive Nasal Drug Delivery Technology
Polyrizon Makes Strong Clinical Progress: Secures Three U.S. Sites for NASARIX™ Trial
Polyrizon Advances Towards Human Clinical Trials: Secures First U.S. Clinical Site for NASARIX™ Allergy Blocker Clinical Trial
Pulse Equity: Emerging Outbreaks - Polyrizon's Approach to Broad and Rapidly Deployable Protection
Polyrizon Announces U.S. Patent Expansion for Its Intranasal Drug Delivery Platform
Polyrizon Announces Filing of European Patent Application for Its Breakthrough Drug Delivery Platform
Polyrizon Ltd. Announces Closing of $3.5 Million Registered Direct and Private Placements
Polyrizon Provides 2025 and Recent Highlights
Polyrizon Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2025
Polyrizon Intends to Acquire up to 20% Stake in Colugo, Developer of Advanced eVTOL Drones for Defense and Urban Air Mobility Applications
Polyrizon Signs an Agreement with Leading Global Preclinical CRO as Part of Clinical Development Program
Polyrizon Announces GMP Manufacturing of Clinical Trial Material (CTM) with Eurofins CDMO AmatsiAquitaine S.A.S for Planned U.S. Clinical Study
Polyrizon Announces Successful Study of its Naloxone Formulation Demonstrating Enhanced Nasal Deposition Profile Versus Commercial Reference Product
Moonage Media Spotlights Polyrizon (Nasdaq: PLRZ): Unveils NASARIX™, Drug-Free Allergy Blocker
Polyrizon Intends to Secure Controlling Stake in Profitable Private Jet Operator
Polyrizon Signs an Agreement to Develop Intranasal Proprietary Non-Hallucinogenic Neuroplastogen Formulation
Polyrizon Intends to Acquire 51% Stake in Global Private Aviation Company
Polyrizon Advances Regulatory Path with Initiation of Usability Study Program for NASARIX™ Allergy Blocker
Polyrizon to Explore Revenue-Generating Investment Opportunities in High-Growth Sectors, Leveraging Strong Cash Position and Debt-Free Balance Sheet
Polyrizon Completes Branding Process for PL-14 Allergy Blocker with Brand Name NASARIX™
Polyrizon Announces New Pre-Clinical Results: PL-14 Demonstrates Significant Allergen-Blocking Performance Compared to a Standard Comparator
As Flu Surge Continues, Polyrizon's Nasal Spray Emerges as Potential Extra Shield Solution for Both Vaccinated and Unvaccinated
Polyrizon to Explore Revenue-Generating Real Asset Opportunities, Leveraging Strong Cash Position and Debt-Free Balance Sheet
Polyrizon Submits Pre-Request for Designation to FDA for PL-16 Viral Blocker Designed to Reduce the Exposure to Influenza and Cold Viruses
Polyrizon Announces Promising Permeation Kinetics Supporting Advancement of Its Intranasal Naloxone Hydrogel Program
Polyrizon Completes FDA Pre-Submission Meeting for PL-14 Allergy Blocker Nasal Spray
From Lab to Global Impact: Polyrizon's Journey to Potentially Redefining Next-Generation Nasal Protection
What Sparked Polyrizon's (PLRZ) 140% After-Hours Stock Surge?
Polyrizon Reports Positive Mucoadhesion Results for Intranasal Naloxone Hydrogel Compared to Marketed Intranasal Naloxone product
Polyrizon Reports Positive Mucoadhesion Results for Intranasal Naloxone Hydrogel Compared to Marketed Intranasal Naloxone product
Polyrizon Announces Successful Completion of Key Manufacturing Upscaling Milestone for Its Nasal Spray Platform
Polyrizon Demonstrates Reversible Broad-Spectrum Viral Blocking by Its Intranasal Barrier-Forming Formulation
Polyrizon Announces Positive Pre-Clinical Results: PL-14 Demonstrates Encouraging Allergen-Blocking Efficacy
Polyrizon Submits Pre-Sub Package to the FDA for PL-14 Allergy Blocker
Polyrizon Reports Successful Intranasal Delivery of PL-14 Allergy Blocker in Latest Study
Polyrizon Regains Compliance with Nasdaq Listing Requirements
Polyrizon Reports Successful Intranasal Delivery of PL-14 Allergy Blocker in Latest Study
Polyrizon Retains Nasdaq Listing Following Hearings Panel
Polyrizon Reports Promising Results Demonstrating Successful Internasal Delivery of its Innovative Hydrogel Formulation for CNS Therapeutics
Polyrizon Announces Receipt of Nasdaq Delisting Notice
Polyrizon Emerges with Positive Preclinical Data on Nasal Protection Platform
Polyrizon Targets $3.15B Epilepsy Market with Preclinical Studies for Innovative Rescue Treatment
Polyrizon Reports Successful Safety Study of a Formulation of PL-14 Allergy Blocker in Human Nasal Tissue Model
Polyrizon Receives Nasdaq Notification Regarding Minimum Bid Requirements
Polyrizon Engages Leading Branding Firm for Strategic Brand Development